This article was originally published by The Defender — Children’s Health Defense’s News & Views Website.
Originally published by Mercola.
Story at a glance:
- The antiviral drug remdesivir, brand name Veklury, is approved for use against COVID-19 despite research showing it lacks effectiveness and can cause high rates of organ failure.
- John Beaudoin is calling for a criminal investigation into remdesivir, citing data that it may have killed 100,000 people in the U.S.
- Beaudoin received all the death certificates in Massachusetts from 2015 to 2022, finding 1,840 excess deaths from acute renal failure from Jan. 1, 2021, to Nov. 30, 2022, which he believes may be due to remdesivir.
- A study published in The Lancet found “no clinical benefit” from the use of remdesivir in hospitalized patients.
- The U.S. government pays hospitals a 20% upcharge on the entire hospital bill when remdesivir is used.